FDA record · warning letter

FDA warning letter: Peaks Curative, LLC dba Peaks (Feb 20, 2026)

On Feb 20, 2026, FDA issued a warning letter to Peaks Curative, LLC dba Peaks under the subject "False & Misleading Claims/Misbranded (Telehealth)". It names semaglutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to Peaks Curative, LLC dba Peaks
Field	What FDA’s record states	Source
Recipient	Peaks Curative, LLC dba Peaks	FDA letter
Location	Not published by FDA	n/a
Letter date	Feb 20, 2026	FDA letter
Posted by FDA	Mar 3, 2026	FDA index
Issuing office	Center for Drug Evaluation and Research (CDER)	FDA letter
Subject	False & Misleading Claims/Misbranded (Telehealth)	FDA letter
MARCS-CMS number	721817	FDA letter
GLP-1 drugs named	Semaglutide	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“As described below, your website’s false or misleading claims concerning compounded semaglutide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].”FDA warning letter to Peaks Curative, LLC dba Peaks, Feb 20, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

And 17 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters